An injury-responsive mmp14b enhancer is required for heart regeneration

Mammals have limited capacity for heart regeneration, whereas zebrafish have extraordinary regeneration abilities. During zebrafish heart regeneration, endothelial cells promote cardiomyocyte cell cycle reentry and myocardial repair, but the mechanisms responsible for promoting an injury microenviro...

Full description

Saved in:
Bibliographic Details
Published inScience advances Vol. 9; no. 48; p. eadh5313
Main Authors Zlatanova, Ivana, Sun, Fei, Wu, Roland S, Chen, Xiaoxin, Lau, Bryan H, Colombier, Pauline, Sinha, Tanvi, Celona, Barbara, Xu, Shan-Mei, Materna, Stefan C, Huang, Guo N, Black, Brian L
Format Journal Article
LanguageEnglish
Published United States American Association for the Advancement of Science 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Mammals have limited capacity for heart regeneration, whereas zebrafish have extraordinary regeneration abilities. During zebrafish heart regeneration, endothelial cells promote cardiomyocyte cell cycle reentry and myocardial repair, but the mechanisms responsible for promoting an injury microenvironment conducive to regeneration remain incompletely defined. Here, we identify the matrix metalloproteinase Mmp14b as an essential regulator of heart regeneration. We identify a TEAD-dependent endothelial enhancer induced by heart injury in zebrafish and mice, and we show that the enhancer is required for regeneration, supporting a role for Hippo signaling upstream of . Last, we show that MMP-14 function in mice is important for the accumulation of Agrin, an essential regulator of neonatal mouse heart regeneration. These findings reveal mechanisms for extracellular matrix remodeling that promote heart regeneration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present Address: Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, Merced, CA 95343, USA.
Present Address: Amgen Inc., South San Francisco, CA 94080 USA.
ISSN:2375-2548
2375-2548
DOI:10.1126/sciadv.adh5313